TURBO UNLIMITED LONG- OPTIONSSCHEIN OHNE STOPP-LOSS-LEVEL - NOVO-NORDISK B TURBO UNLIMITED LONG- OPTIONSSCHEIN OHNE STOPP-LOSS-LEVEL - NOVO-NORDISK B Stock
Certificat
DE000CJ9DFZ7
| Market Closed - Boerse Frankfurt Warrants 15:37:24 2024-05-31 EDT | ||
| 20.13 EUR | +0.75% |
|
| 1 month | +3.45% | ||
| 3 months | +15.20% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
NOVO NORDISK A/S
Latest news about NOVO NORDISK A/S
| Date | Price | Change |
|---|---|---|
| 24-05-31 | 20.08 | +0.50% |
| 24-05-30 | 19.98 | +0.10% |
| 24-05-29 | 19.96 | +0.05% |
| 24-05-28 | 19.95 | -0.89% |
| 24-05-27 | 20.13 | -1.28% |
Real-time Boerse Frankfurt Warrants
Last update May 31, 2024 at 03:37 pm
More quotesStatic data
| Product type | Warrant Knock-Out senza Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | NOVO NORDISK A/S |
| Issuer | 
Société Générale
|
| WKN | CJ9DFZ |
| ISIN | DE000CJ9DFZ7 |
| Date issued | 2019-02-04 |
| Strike | 171.4 kr |
| Maturity | Unlimited |
| Parity | 5 : 1 |
| Emission price | 0.18 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 20.76 € |
|---|---|
| Lowest since issue | 0.11 € |
Company Profile
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
-
Consensus: Novo Nordisk A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
927.3
DKK
Average target price
917.2
DKK
Spread / Average Target
-1.09%
- Stock Market
- Certificates
- Certificat
